The tardive dyskinesia market is undergoing a notable transformation as clinical awareness grows and targeted pharmacological options replace older supportive management approaches. Valued at roughly USD 4,400 million across the 7MM in 2025, the market is projected to reach approximately USD 10,600 million by 2036, reflecting an 8.1% CAGR over the forecast period. This growth is being driven less by shifts between competing brands and more by rising diagnosis rates and expanding treatment penetration among an eligible but still largely undertreated patient population.
Understanding Tardive Dyskinesia Diagnosis and Epidemiology
Tardive dyskinesia diagnosis remains clinically challenging, relying on a history of exposure to dopamine receptor-blocking agents combined with characteristic involuntary movements of the face, mouth, tongue, and jaw. Tools such as the Abnormal Involuntary Movement Scale support earlier identification, yet frequent overlap with broader extrapyramidal symptoms continues to delay accurate recognition. On the tardive dyskinesia epidemiology front, DelveInsight estimates roughly 1,777,000 prevalent cases across the 7MM in 2025, with the United States accounting for nearly 40% of the total antipsychotic drug user population. Among the EU4 and UK, Germany reported the highest number of prevalent cases, while the UK recorded the lowest incident cases. In the US, moderate-to-severe cases made up nearly 60% of diagnosed prevalence, with mild cases comprising the remainder.
US and Regional Market Dynamics
The US tardive dyskinesia therapeutics market dominates global revenue, accounting for nearly 98% of total market size in 2025. This concentration reflects earlier drug approvals, stronger diagnostic infrastructure, and broader reimbursement support compared with other regions. The US tardive dyskinesia treatment market continues to benefit from established VMAT2 inhibitor adoption, though underdiagnosis persists in long-term care settings. Beyond the US, the Japan tardive dyskinesia therapeutics market represents a smaller but growing opportunity, supported by valbenazine’s 2022 approval in the country. Adjacent indication markets, including the Germany chorea market and Italy chorea market, are shaped by shared VMAT2 inhibitor mechanisms, since deutetrabenazine also treats Huntington’s disease-associated chorea and received EU marketing authorization in January 2026.
Approved Therapies and Mechanism of Action
Current standard-of-care treatment is anchored by two approved VMAT2 inhibitors. Ingrezza MOA centers on valbenazine’s selective inhibition of vesicular monoamine transporter 2 without meaningful binding to dopaminergic, serotonergic, adrenergic, or muscarinic receptors, distinguishing its valbenazine MOA profile from earlier non-selective agents. Available in 40 mg, 60 mg, and 80 mg capsules, INGREZZA was launched in 2017, with an oral granule formulation, INGREZZA SPRINKLE, approved in 2024. Similarly, Austedo MOA reflects deutetrabenazine’s VMAT2-inhibiting action, approved by Teva Pharmaceuticals in 2017, with the once-daily AUSTEDO XR formulation added in 2023. Valbenazine maintains a competitive edge in the valbenazine market due to once-daily dosing, higher treatment persistence, and nearly two-fold greater VMAT2 target occupancy compared with deutetrabenazine, positioning it strongly within the broader deutetrabenazine market rivalry.
TD Treatment Market Landscape and Pipeline Outlook
The TD treatment market, synonymous with the tardive dyskinesia drugs market, remains predominantly small-molecule driven and centered on VMAT2 modulation. The tardive dyskinesia pipeline is relatively limited, concentrated in early- to mid-stage development. Key tardive dyskinesia companies advancing candidates include Neurocrine Biosciences, developing NBI-‘890 (currently in Phase II), and SOM Biotech, progressing SOM3355 through Phase IIb trials using a multimodal mechanism combining selective β1-adrenergic modulation—sometimes referenced by its component bevantolol—with VMAT1 and VMAT2 inhibition. Acadia Pharmaceuticals’ ACP-2712, a GPR88 agonist, is in Phase I, with a first-in-human study planned for Q4 2026. Ongoing tardive dyskinesia clinical trials, including Neurocrine’s January 2026 initiation of a Phase II study for NBI-1065890, reflect continued innovation within the VMAT2 inhibitor market.
Broader Movement Disorder and Chorea Market Context
Positioned within the larger movement disorder market and movement disorder therapeutics market, TD therapies increasingly overlap with the chorea market, given shared VMAT2 mechanisms across indications. This cross-indication relevance extends into the chorea treatment market, where deutetrabenazine’s dual approval strengthens its commercial footprint. Overall, sustained growth across the tardive dyskinesia therapeutics market, alongside expansion into next-generation mechanisms such as GPR88 agonists and P5P analogues, underscores a VMAT2 inhibitors-led future while highlighting persistent unmet needs around underdiagnosis, standardized guidelines, and access disparities affecting the broader TD therapeutics market.
Latest Reports Offered by Delveinsight
aesthetic implants market | alopecia market | alpha antitrypsin market | alpha-mannosidosis market | androgenetic alopecia market | anterior cruciate ligament injuries market | aplastic anemia market | arteriovenous malformations market | asperger syndrome market | atherectomy devices market | beta thalassemia market | blood purification devices market | bone neoplasms market | bone resorption market | breast biopsy market | burn market | c-met non-small cell lung cancer market | cancer vaccines market | car t cell therapy for nhl market | car t-cell therapy for non-hodgkin’s lymphoma market | cardiac monitoring system market | cardiac rhythm management devices market | cart-related neurotoxicity market | castration-resistant prostate cancer market |
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
